{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:50:06Z","timestamp":1780725006858,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shirley E. Noland Foundation","award":["RP0251"],"award-info":[{"award-number":["RP0251"]}]},{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["2U54 MD006882-06"],"award-info":[{"award-number":["2U54 MD006882-06"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["F.V.2501\/531-HRD\/2016-HR"],"award-info":[{"award-number":["F.V.2501\/531-HRD\/2016-HR"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,2,15]]},"DOI":"10.1007\/s10637-018-0594-9","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T02:36:14Z","timestamp":1526351774000},"page":"27-34","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Copper-tolfenamic acid: evaluation of stability and anti-cancer activity"],"prefix":"10.1007","volume":"37","author":[{"given":"Myrna","family":"Hurtado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh T.","family":"Sankpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deondra T.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajasekhar","family":"Maram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafid","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj K.","family":"Gurung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Simecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin A.","family":"Holder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyaz","family":"Basha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"issue":"2","key":"594_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S1367-5931(02)00298-3","volume":"6","author":"S Puig","year":"2002","unstructured":"Puig S, Thiele DJ (2002) Molecular mechanisms of copper uptake and distribution. Curr Opin Chem Biol 6(2):171\u2013180","journal-title":"Curr Opin Chem Biol"},{"issue":"6","key":"594_CR2","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10534-012-9578-y","volume":"25","author":"P Szymanski","year":"2012","unstructured":"Szymanski P, Fraczek T, Markowicz M, Mikiciuk-Olasik E (2012) Development of copper based drugs, radiopharmaceuticals and medical materials. Biometals 25(6):1089\u20131112. https:\/\/doi.org\/10.1007\/s10534-012-9578-y","journal-title":"Biometals"},{"issue":"Suppl A","key":"594_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0305-7372(85)90026-X","volume":"12","author":"EB Douple","year":"1985","unstructured":"Douple EB, Richmond RC, O'Hara JA, Coughlin CT (1985) Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 12(Suppl A):111\u2013124","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"594_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1056\/NEJM197902083000605","volume":"300","author":"LH Einhorn","year":"1979","unstructured":"Einhorn LH, Williams SD (1979) The role of cis-platinum in solid-tumor therapy. N Engl J Med 300(6):289\u2013291. https:\/\/doi.org\/10.1056\/NEJM197902083000605","journal-title":"N Engl J Med"},{"issue":"1","key":"594_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bdd.2510020102","volume":"2","author":"DF Long","year":"1981","unstructured":"Long DF, Repta AJ (1981) Cisplatin: chemistry, distribution and biotransformation. Biopharm Drug Dispos 2(1):1\u201316","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"594_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.2165\/00003495-198937020-00005","volume":"37","author":"AJ Wagstaff","year":"1989","unstructured":"Wagstaff AJ, Ward A, Benfield P, Heel RC (1989) Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 37(2):162\u2013190","journal-title":"Drugs"},{"key":"594_CR7","doi-asserted-by":"crossref","unstructured":"Woloschuk DM, Pruemer JM, Cluxton RJ, Jr. (1988) Carboplatin: a new cisplatin analog. Drug Intell Clin Pharm 22 (11):843\u2013849","DOI":"10.1177\/106002808802201101"},{"key":"594_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.msec.2016.05.014","volume":"68","author":"A Pramanik","year":"2016","unstructured":"Pramanik A, Laha D, Dash SK, Chattopadhyay S, Roy S, Das DK, Pramanik P, Karmakar P (2016) An in-vivo study for targeted delivery of copper-organic complex to breast cancer using chitosan polymer nanoparticles. Mater Sci Eng C Mater Biol Appl 68:327\u2013337. https:\/\/doi.org\/10.1016\/j.msec.2016.05.014","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"6","key":"594_CR9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.molonc.2015.02.007","volume":"9","author":"JL Allensworth","year":"2015","unstructured":"Allensworth JL, Evans MK, Bertucci F, Aldrich AJ, Festa RA, Finetti P, Ueno NT, Safi R, McDonnell DP, Thiele DJ, Van Laere S, Devi GR (2015) Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. Mol Oncol 9(6):1155\u20131168. https:\/\/doi.org\/10.1016\/j.molonc.2015.02.007","journal-title":"Mol Oncol"},{"issue":"1","key":"594_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/1061186X.2013.832768","volume":"22","author":"A Pramanik","year":"2014","unstructured":"Pramanik A, Laha D, Pramanik P, Karmakar P (2014) A novel drug \"copper acetylacetonate\" loaded in folic acid-tagged chitosan nanoparticle for efficient cancer cell targeting. J Drug Target 22(1):23\u201333. https:\/\/doi.org\/10.3109\/1061186X.2013.832768","journal-title":"J Drug Target"},{"issue":"1","key":"594_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4255\/mcpharmacol.09.05","volume":"1","author":"ER Rayburn","year":"2009","unstructured":"Rayburn ER, Ezell SJ, Zhang R (2009) Anti-inflammatory agents for Cancer therapy. Mol Cell Pharmacol 1(1):29\u201343. https:\/\/doi.org\/10.4255\/mcpharmacol.09.05","journal-title":"Mol Cell Pharmacol"},{"issue":"4","key":"594_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","volume":"94","author":"MJ Thun","year":"2002","unstructured":"Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94(4):252\u2013266","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"594_CR13","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.amjmed.2017.06.028","volume":"130","author":"DH Solomon","year":"2017","unstructured":"Solomon DH, Husni ME, Libby PA, Yeomans ND, Lincoff AM, Lupsilonscher TF, Menon V, Brennan DM, Wisniewski LM, Nissen SE, Borer JS (2017) The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial. Am J Med 130(12):1415\u20131422 e1414. https:\/\/doi.org\/10.1016\/j.amjmed.2017.06.028","journal-title":"Am J Med"},{"issue":"1","key":"594_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/00325481.2018.1412799","volume":"130","author":"C Walker","year":"2018","unstructured":"Walker C, Biasucci LM (2018) Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited. Postgrad Med 130(1):55\u201371. https:\/\/doi.org\/10.1080\/00325481.2018.1412799","journal-title":"Postgrad Med"},{"issue":"12","key":"594_CR15","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/jnci\/djj232","volume":"98","author":"M Abdelrahim","year":"2006","unstructured":"Abdelrahim M, Baker CH, Abbruzzese JL, Safe S (2006) Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 98(12):855\u2013868. https:\/\/doi.org\/10.1093\/jnci\/djj232","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"594_CR16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1158\/1535-7163.MCT-08-1097","volume":"8","author":"X Liu","year":"2009","unstructured":"Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S (2009) The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. Mol Cancer Ther 8(5):1207\u20131217. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-1097","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 1","key":"594_CR17","doi-asserted-by":"publisher","first-page":"E53","DOI":"10.1002\/mc.22010","volume":"53","author":"S Pathi","year":"2014","unstructured":"Pathi S, Li X, Safe S (2014) Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors. Mol Carcinog 53(Suppl 1):E53\u2013E61. https:\/\/doi.org\/10.1002\/mc.22010","journal-title":"Mol Carcinog"},{"issue":"12","key":"594_CR18","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1093\/carcin\/bgt250","volume":"34","author":"X Zhang","year":"2013","unstructured":"Zhang X, Min KW, Liggett J, Baek SJ (2013) Disruption of the transforming growth factor-beta pathway by tolfenamic acid via the ERK MAP kinase pathway. Carcinogenesis 34(12):2900\u20132907. https:\/\/doi.org\/10.1093\/carcin\/bgt250","journal-title":"Carcinogenesis"},{"issue":"3","key":"594_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1158\/1535-7163.MCT-08-0405","volume":"8","author":"S Konduri","year":"2009","unstructured":"Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M (2009) Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 8(3):533\u2013542. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0405","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"594_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1021\/jm7013259","volume":"51","author":"ME Katsarou","year":"2008","unstructured":"Katsarou ME, Efthimiadou EK, Psomas G, Karaliota A, Vourloumis D (2008) Novel copper(II) complex of N-propyl-norfloxacin and 1,10-phenanthroline with enhanced antileukemic and DNA nuclease activities. J Med Chem 51(3):470\u2013478. https:\/\/doi.org\/10.1021\/jm7013259","journal-title":"J Med Chem"},{"issue":"10","key":"594_CR21","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.4155\/fmc.10.234","volume":"2","author":"SJ Tan","year":"2010","unstructured":"Tan SJ, Yan YK, Lee PP, Lim KH (2010) Copper, gold and silver compounds as potential new anti-tumor metallodrugs. Future Med Chem 2(10):1591\u20131608. https:\/\/doi.org\/10.4155\/fmc.10.234","journal-title":"Future Med Chem"},{"key":"594_CR22","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/370345","volume":"2011","author":"Y Manso","year":"2011","unstructured":"Manso Y, Comes G, Hidalgo J, Bush AI, Adlard PA (2011) Copper modulation as a therapy for Alzheimer's disease? Int J Alzheimers Dis 2011:370345. https:\/\/doi.org\/10.4061\/2011\/370345","journal-title":"Int J Alzheimers Dis"},{"key":"594_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jinorgbio.2015.02.019","volume":"149","author":"A Tarushi","year":"2015","unstructured":"Tarushi A, Perontsis S, Hatzidimitriou AG, Papadopoulos AN, Kessissoglou DP, Psomas G (2015) Copper(II) complexes with the non-steroidal anti-inflammatory drug tolfenamic acid: structure and biological features. J Inorg Biochem 149:68\u201379. https:\/\/doi.org\/10.1016\/j.jinorgbio.2015.02.019","journal-title":"J Inorg Biochem"},{"issue":"11","key":"594_CR24","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.160351","volume":"3","author":"AA Altaf","year":"2016","unstructured":"Altaf AA, Hashmat U, Yousaf M, Lal B, Ullah S, Holder AA, Badshah A (2016) Synthesis and characterization of azo-guanidine based alcoholic media naked eye DNA sensor. R Soc Open Sci 3(11):160351. https:\/\/doi.org\/10.1098\/rsos.160351","journal-title":"R Soc Open Sci"},{"issue":"2","key":"594_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s10637-016-0417-9","volume":"35","author":"S Shelake","year":"2017","unstructured":"Shelake S, Sankpal UT, Paul Bowman W, Wise M, Ray A, Basha R (2017) Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth. Investig New Drugs 35(2):158\u2013165. https:\/\/doi.org\/10.1007\/s10637-016-0417-9","journal-title":"Investig New Drugs"},{"issue":"7","key":"594_CR26","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1021\/cb400198p","volume":"8","author":"MA Cater","year":"2013","unstructured":"Cater MA, Pearson HB, Wolyniec K, Klaver P, Bilandzic M, Paterson BM, Bush AI, Humbert PO, La Fontaine S, Donnelly PS, Haupt Y (2013) Increasing intracellular bioavailable copper selectively targets prostate cancer cells. ACS Chem Biol 8(7):1621\u20131631. https:\/\/doi.org\/10.1021\/cb400198p","journal-title":"ACS Chem Biol"},{"issue":"11","key":"594_CR27","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1039\/C5MT00149H","volume":"7","author":"D Denoyer","year":"2015","unstructured":"Denoyer D, Masaldan S, La Fontaine S, Cater MA (2015) Targeting copper in cancer therapy: 'Copper that Cancer'. Metallomics 7(11):1459\u20131476. https:\/\/doi.org\/10.1039\/c5mt00149h","journal-title":"Metallomics"},{"issue":"21","key":"594_CR28","doi-asserted-by":"publisher","first-page":"R877","DOI":"10.1016\/j.cub.2011.09.040","volume":"21","author":"RA Festa","year":"2011","unstructured":"Festa RA, Thiele DJ (2011) Copper: an essential metal in biology. Curr Biol 21(21):R877\u2013R883. https:\/\/doi.org\/10.1016\/j.cub.2011.09.040","journal-title":"Curr Biol"},{"issue":"1","key":"594_CR29","first-page":"81","volume":"37","author":"Y Xiao","year":"2010","unstructured":"Xiao Y, Chen DI, Zhang X, Cui Q, Fan Y, Bi C, Dou QP (2010) Molecular study on copper-mediated tumor proteasome inhibition and cell death. Int J Oncol 37(1):81\u201387","journal-title":"Int J Oncol"},{"issue":"10","key":"594_CR30","first-page":"2165","volume":"26","author":"VC Barry","year":"1966","unstructured":"Barry VC, Conalty ML, O'Sullivan JF (1966) Anticancer activity of bisthiosemicarbazones of methylglyoxal. Cancer Res 26(10):2165\u20132168","journal-title":"Cancer Res"},{"issue":"11","key":"594_CR31","first-page":"1290","volume":"18","author":"FA French","year":"1958","unstructured":"French FA, Freedlander BL (1958) Carcinostatic action of polycarbonyl compounds and their derivatives. IV. Glyoxal bis (thiosemicarbazone) and derivatives. Cancer Res 18(11):1290\u20131300","journal-title":"Cancer Res"},{"key":"594_CR32","first-page":"367","volume":"24","author":"HG Petering","year":"1964","unstructured":"Petering HG, Buskirk HH, Underwood GE (1964) The anti-tumor activity of 2-Keto-3-Ethoxybutyraldehyde Bis(Thiosemicarbazone) and related compounds. Cancer Res 24:367\u2013372","journal-title":"Cancer Res"},{"issue":"2","key":"594_CR33","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3892\/ijo.2016.3542","volume":"49","author":"Z Zhang","year":"2016","unstructured":"Zhang Z, Wang H, Wang Q, Yan M, Wang H, Bi C, Sun S, Fan Y (2016) Anticancer activity and computational modeling of ternary copper (II) complexes with 3-indolecarboxylic acid and 1,10-phenanthroline. Int J Oncol 49(2):691\u2013699. https:\/\/doi.org\/10.3892\/ijo.2016.3542","journal-title":"Int J Oncol"},{"issue":"1","key":"594_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1021\/jm00223a024","volume":"19","author":"JR Sorenson","year":"1976","unstructured":"Sorenson JR (1976) Copper chelates as possible active forms of the antiarthritic agents. J Med Chem 19(1):135\u2013148","journal-title":"J Med Chem"},{"key":"594_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-4584-1","volume-title":"Biology of copper complexes. Biology of copper complexes","author":"JR Sorenson","year":"1987","unstructured":"Sorenson JR (1987) Biology of copper complexes. Biology of copper complexes. Humana Press, Clifton"},{"key":"594_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0079-6468(08)70246-7","volume":"26","author":"JR Sorenson","year":"1989","unstructured":"Sorenson JR (1989) Copper complexes offer a physiological approach to treatment of chronic diseases. Prog Med Chem 26:437\u2013568","journal-title":"Prog Med Chem"},{"issue":"5","key":"594_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1006\/phrs.1997.0247","volume":"36","author":"L Franco","year":"1997","unstructured":"Franco L, Doria D (1997) Prostaglandins and nitric oxide in copper-complex mediated protection against ethanol-induced gastric damage. Pharmacol Res 36(5):395\u2013399. https:\/\/doi.org\/10.1006\/phrs.1997.0247","journal-title":"Pharmacol Res"},{"issue":"2","key":"594_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1054\/plef.1999.0078","volume":"61","author":"S Sakuma","year":"1999","unstructured":"Sakuma S, Fujimoto Y, Kitao A, Sakamoto H, Nishida H, Fujita T (1999) Simultaneous measurement of prostaglandin and arachidonoyl CoA formed from arachidonic acid in rabbit kidney medulla microsomes: the roles of Zn2+ and Cu2+ as modulators of formation of the two products. Prostaglandins Leukot Essent Fatty Acids 61(2):105\u2013112. https:\/\/doi.org\/10.1054\/plef.1999.0078","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"3","key":"594_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0952-3278(96)90016-2","volume":"54","author":"S Sakuma","year":"1996","unstructured":"Sakuma S, Fujimoto Y, Miyata Y, Ohno M, Nishida H, Fujita T (1996) Effects of Fe(2+), Zn(2+), cu(2+) and se(4+) on the synthesis and catabolism of prostaglandins in rabbit gastric antral mucosa. Prostaglandins Leukot Essent Fatty Acids 54(3):193\u2013197","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"3","key":"594_CR40","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jn\/129.3.596","volume":"129","author":"RG Hopkins","year":"1999","unstructured":"Hopkins RG, Failla ML (1999) Transcriptional regulation of interleukin-2 gene expression is impaired by copper deficiency in Jurkat human T lymphocytes. J Nutr 129(3):596\u2013601","journal-title":"J Nutr"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0594-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0594-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0594-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:27:55Z","timestamp":1678559275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0594-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2,15]]}},"alternative-id":["594"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0594-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]},"assertion":[{"value":"13 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M Hurtado declares that she has no conflict of interest. U T Sankpal declares that he has no conflict of interest. Jaya Chhabra declares that she has no conflict of interest. Deondra T. Brown declares that she has no conflict of interest. Rafid Patel declares that he has no conflict of interest. Raj K. Gurung declares that he has no conflict of interest. Jerry Simecka declares that he has no conflict of interest. Alvin A. Holder declares that he has no conflict of interest. Riyaz Basha declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This manuscript does not contain any experiments with human subjects or animals conducted by any of the contributing authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"It is a preclinical study. Therefore, formal consent is not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}